FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL DISEASES

REGISTER FOR WEBCAST AND TELECONFERENCE CALL AT 11.30am AEDT TODAY
Actinogen will host a webcast and teleconference call at 11.30am AEDT today to provide a strategic update on its clinical development plans and the capital raising as set out in an investor presentation released in a separate announcement to the ASX this morning.
Click here to register for the webcast and teleconference
Depression selected as our third disease program, expanding Fragile X Syndrome program and launches capital raising
We are pleased to announce several strategic initiatives. Major Depressive Disorder (MDD) selected as third indication for Xanamem, Phase 2 XanaFX clinical trial for patients with Fragile X Syndrome (FXS) expanded and launches capital raising.
View ASX Announcement
Strategic Update & Capital Raising Investor Presentation
The investor presentation provides a strategic update on the company’s clinical development pipeline and the capital raising. A webcast and teleconference call will be held today at 11.30 am AEDT.
View ASX Announcement
Actinogen receives positive Pre-IND FDA advice for FXS
Actinogen received written supportive US FDA advice in response to its Pre-Investigational New Drug Application (Pre-IND) submission for its FXS program. “The FDA’s positive Pre-IND advice for FXS marks a significant milestone in the clinical development of our second disease program. It provides greater confidence that we will obtain support from the FDA for the investigation of Xanamem in this disease that has a high unmet medical need for effective therapies." said Dr Steven Gourlay
View ASX Announcement
Previous
Next

About Us

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical’s lead drug candidate, Xanamem®has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company is conducting a range of quality Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.